Literature DB >> 15088772

An overview of serum antibody responses to influenza virus antigens.

R B Couch1.   

Abstract

Serum antibody responses after exposure to influenza virus antigens follow expected patterns for protein antigens. Induction of primary responses occurs in organized lymphoid tissues while secondary responses may occur in the periphery; in primary responses, IgM antibody is initially dominant whereas IgG antibody is dominant in secondary responses. Serum antibody responses have been ascribed to the HA, NA, M2, NP, and M1 proteins. Only the HA and NA antibodies have been shown to provide immunity in humans. Anti-HA antibody mediates neutralization and serum IgG anti-HA antibody is the dominant antibody in the lower respiratory tract. Since evidence indicates that most infections are acquired by the airborne route with deposition of virus in the lower respiratory tract, serum IgG anti-HA antibody is the primary mediator of immunity to influenza. Homotypic immunity is high for decades. Both antigenic drift and shift of the surface antigens reduce the effectiveness of antibody to the HA and NA and lead to renewed susceptibility to infection. Nevertheless, heterotypic antibody can convey substantial immunity with the degree dependent upon the extent of cross-reactivity for the infecting virus antigens. While serum anti-HA antibody is the major need for optimal immunity to influenza, a full complement of immune modalities is desirable to ensure maximum immunity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15088772

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  29 in total

Review 1.  Emerging Infections of CNS: Avian Influenza A Virus, Rift Valley Fever Virus and Human Parechovirus.

Authors:  Clayton A Wiley; Nitin Bhardwaj; Ted M Ross; Stephanie J Bissel
Journal:  Brain Pathol       Date:  2015-09       Impact factor: 6.508

2.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

3.  Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines.

Authors:  Xiao-Song He; Tyson H Holmes; Caiqiu Zhang; Kutubuddin Mahmood; George W Kemble; David B Lewis; Cornelia L Dekker; Harry B Greenberg; Ann M Arvin
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity.

Authors:  Jerome P Jayasekera; E Ashley Moseman; Michael C Carroll
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

5.  Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.

Authors:  Robert B Couch; Patricia Winokur; Rebecca Brady; Robert Belshe; Wilbur H Chen; Thomas R Cate; Bryndis Sigurdardottir; Amy Hoeper; Irene L Graham; Robert Edelman; Fenhua He; Diane Nino; Jose Capellan; Frederick L Ruben
Journal:  Vaccine       Date:  2007-09-14       Impact factor: 3.641

Review 6.  The Density Code for the Development of a Vaccine?

Authors:  Wei Cheng
Journal:  J Pharm Sci       Date:  2016-09-17       Impact factor: 3.534

7.  Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

Authors:  Sanae Sasaki; Maria C Jaimes; Tyson H Holmes; Cornelia L Dekker; Kutubuddin Mahmood; George W Kemble; Ann M Arvin; Harry B Greenberg
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

8.  Broad humoral and cellular immunity elicited by a bivalent DNA vaccine encoding HA and NP genes from an H5N1 virus.

Authors:  Ke Xu; Zhi-Yang Ling; Liang Sun; Ying Xu; Chao Bian; Yuan He; Wei Lu; Ze Chen; Bing Sun
Journal:  Viral Immunol       Date:  2011-02       Impact factor: 2.257

Review 9.  Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients.

Authors:  Arnt-Ove Hovden; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

10.  Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza.

Authors:  Garry W Lynch; Paul Selleck; John S Sullivan
Journal:  J Mol Genet Med       Date:  2009-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.